Semaglutide and tirzepatide address GLP-1 receptor signalling but if insulin resistance is driven by cortisol dysregulation, thyroid pathology, or androgen excess (common in PCOS), a prescription alone will not resolve it
The PRMR Hospital Recommendation Group met on January 15 and 16, 2025, to review measures included by the Secretary on the publicly available 2024 Measures Under Consideration List (MUC List), including the Emergency Care Access & Timeliness eCQM (MUC2024-095), and provided additional recommendations on the potential use of this measure
Excess melanin production leads to hyperpigmentation, which manifests as discolored patches
Stimulation of these receptors by GLP-1RAs may lead to cellular overgrowth, hyperplasia, chronic low-grade, or acute inflammation